# Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

> **Open Intelligence Dossier** · First detected: 2026-10-23 16:20 UTC · Category: Business

## Executive Summary
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer" is generating significant coverage in the Business category, with 8 articles from 7 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Investing.com Canada, BioSpace, Targeted Oncology and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investing.com India | Form 8K Tango Therapeutics Inc For: 23 October By Investing.com | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdHI1OGxLN3FIWmt1dm8tbGo1aHdxS1E3Wk5pckdSVjRTVDFxNFFvMDl6QWQxa1ZLRWtCbWtibWNGSlV0bUlXNnlXMUNGTk1XY3QyOEZCY2RzODU3UkNyeExVNmk1MlNHTDZMTlJTczFVNXdOYXhCanNKbDFOYzdkbFNZZmxOUEMxOEJOQlZZY0daZVE4Nkw0UmhJd2ppd0JzdjNWSG5ReHg1Zw?oc=5) |
| Investing.com Canada | Form 8K Tango Therapeutics Inc For: 23 October By Investing.com | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxOUlVJeHhHRHFqWGpCcUJYdnpPdXU2X3ctNk9PQ3RtVlFucDh5Slo0RDFjdXR2YXNJZWVXLUc5c3lHdXY0aXg2VUVMdU1RclNzaHlrYUNTam1Zekp5RHZxVERNd0VhN1Q4S0tteTNNWVh3ckNxemhOTXZoYmU0TVM2dTJ1X2FaSDd2Q1QzR3VJc2VVN0E1bkJCbzBwWmFSMEx0OWZ2dDNYWVdBUQ?oc=5) |
| BioSpace | ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3 | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxPU2Q2aUttMlRDVnFIM3czd3RCQXBaUmhIUlFtZ09oaDZhazl3NWlKajR2TXBsdjROZFNrMUVSZXItbzVyVkR1RG4xT2MzTXBGVlNXS3lfWHFiX2xwS0d4SGFMZUlrdVZER0tQdWdvbVhkRF9OSFFIYl9OajN6RzliOTFnM0oybDJVanVqNDVUQjRUb2FFV25RaURDbnRGTUlUWjk4ejJtZmd3VVM2OC1KNEg4ekhneHpNX1VsQU5zZ2ZMNnlUeFBWcmhWSFFwZllr?oc=5) |
| Targeted Oncology | Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNSFB3Z0Y2b2JQZzNWTmc4RDBVMXNabE5yZ2RvczFMRnU3R2p5RUd3SDJmb2lVYjhXQUQ3NXhNSWNwM01lNVN6NkdUY0VRY2tvOTRMLXc3NDVpYzVSNDZBRm84b0U3SjFVQVNMVnkzWmt5MTM1YWRObXdJY0d2UmpnRTMxMWlMVHlkSEZnUGlZWW5lODFGN3VKNlJESkNIQWc?oc=5) |
| FirstWord Pharma | ESMO26: Tango's updated pancreatic cancer data gets chilly market reception | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5hTUlLR0E2eGl0N04ySHh5ekgwOW9UYUwzVUlfdVE1T1Zvd09rV192eFFwRTc0MHpxa3dNUFVRaWRsZF9CcDRvWEFRRHZJdUdtYVp3?oc=5) |
| Investor's Business Daily | How Tango Improved On Revolution's 'Unprecedented' Results | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWGJ5M1E2Z2VXN1lHZk5Eb01KZ3UwNU9CY2hFZ3QwYnR2TWJxVXNEZDdyNFRSdXlBMGJCQlVjcDVlaTBxOGRwM18waXk1R0NHeGtOOF9nU25YUWZWR1h6TEJVbDRhUEtoNVcwdkFIUHJUeFBfNTZINHV3X3FaNXB1T0YwQUtZdllWZmNsMDctVzVtdjZUZUdHa3JxQXlrQlFnRmFxNFNseXRMZw?oc=5) |
| STAT | Tango builds on Revolution Medicines’ pancreatic cancer success | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxOUFRubkRfZTA2MWRmWk10YlNFRWdOUXB6VTJodjZDOFBvd19SNm9hcGwwY0pMQW5HeTFSWEp4Nm1LVm10aG1pRElkTmppUlpyTXJmUnZsWi1mRTJ6R01FbEgxVTJOOVVFU2dheHlETWY4SGxpeE1UZHhIT1VMaHZCTXJCRHNJb0FtWF85bF9Mc291R2M2MXFv?oc=5) |
| Endpoints News | Tango combo clears Rasonque bar, Takeda’s Innovent bet gets early returns, plus more from #ESMO26 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxNRFFBaXIydEczblV6T2x3Xy1jNGI2VEFDYW8xZmpnMDBnQUlpOWVtbXpmallCT2txdGd1OE4wdnZNUjdvTmpoMVVPRUFfdXhROVp6YUVuM24xdHJWTkx6ZGRxM2ZzdGZKeFl6NnFuUmdCTlJkdW4xcHI2dDRVOVBnWnNhOTUtQXhQa0t5Zi03MXJCVW44MXFobjVUM2VfQm9MYmlxSDd5QVgyQk9ubEk4RmlQZzdrc0E?oc=5) |
| STAT | Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxNa0wzR2ZBQ2tGamotM0EwakVKVTMyWFFNVDU2bU56b3lFUm8yalp0UVRTRGtEYm4ta3hwYnNoajNXc015NmViajliN2dWbkw4cHRYbzZnaDVETGVNc3MxblNpUTV2eDFxN3RmZ0wyaVpiUDdIekJyUnR2Z2s3eTJUVWJqNHk2Qlk1d2lwSjJ3dVlIdDdCdjJseDZuN3JCVng4YWt2aVkxZHVTTmFSWXBFZHZDYVpWVHR1cHJEN3RRUQ?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-23/tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for-advanced*